Anecortave Acetate is primarily used in ophthalmology for its anti-angiogenic properties, making it effective in treating eye conditions related to abnormal blood vessel growth. It is particularly applied in managing age-related macular degeneration (AMD), a leading cause of vision loss in older adults. By inhibiting the formation of new blood vessels in the retina, it helps prevent the progression of wet AMD, preserving vision. Additionally, it has been explored for its potential in treating other ocular disorders, such as diabetic retinopathy and glaucoma, where abnormal vascularization contributes to disease progression. Its administration as a posterior juxtascleral depot allows for localized and sustained delivery, minimizing systemic side effects.